[1]
|
Fowkes, F.G., Aboyans, V., Fowkes, F.J., et al. (2017) Peripheral Artery Disease: Epidemiology and Global Perspec-tives. Nature Reviews Cardiology, 14, 156-170. https://doi.org/10.1038/nrcardio.2016.179
|
[2]
|
Aboyans, V., Ricco, J.-B., Bartelink, M.-L.E.L., et al. (2018) Editor’s Choice—2017 ESC Guidelines on the Diagnosis and Treatment of Pe-ripheral Arterial Diseases, in Collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 55, 305-368.
https://doi.org/10.1016/j.ejvs.2017.07.018
|
[3]
|
De Carlo, M., Schlager, O., Mazzolai, L., et al. (2023) Antithrom-botic Therapy Following Revascularization for Chronic Limb-Threatening Ischaemia: A European Survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal—Cardiovascular Pharmacother-apy, 9, 201-207.
https://doi.org/10.1093/ehjcvp/pvac055
|
[4]
|
Fowkes, F.G., Price, J.F., Stewart, M.C., et al. (2010) Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial. JAMA, 303, 841-848.
https://doi.org/10.1001/jama.2010.221
|
[5]
|
Belch, J., Maccuish, A., Campbell, I., et al. (2008) The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) Trial: Factorial Randomised Placebo Controlled Trial of As-pirin and Antioxidants in Patients with Diabetes and Asymptomatic Peripheral Arterial Disease. BMJ, 337, Article No. a1840. https://doi.org/10.1136/bmj.a1840
|
[6]
|
Aboyans, V., Ricco, J.-B., Bartelink, M.-L.E.L., et al. (2018) 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration with the European So-ciety for Vascular Surgery (ESVS): Document Covering Atherosclerotic Disease of Extracranial Carotid and Vertebral, Mesenteric, Renal, Upper and Lower Extremity Arteries Endorsed By: The European Stroke Organization (ESO) the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal, 39, 763-816. https://doi.org/10.1093/eurheartj/ehx095
|
[7]
|
US Preventive Services Task Force (2022) Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA, 327, 1577-1584. https://doi.org/10.1001/jama.2022.4983
|
[8]
|
CAPRIE Steering Committee (1996) A Randomised, Blinded, Trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet, 348, 1329-1339. https://doi.org/10.1016/S0140-6736(96)09457-3
|
[9]
|
Bhatt, D.L., Fox, K.A., Hacke, W., et al. (2006) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 354, 1706-1717. https://doi.org/10.1056/NEJMoa060989
|
[10]
|
Burdess, A., Nimmo, A.F., Garden, O.J., et al. (2010) Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Is-chemia. Annals of Surgery, 252, 37-42.
https://doi.org/10.1097/SLA.0b013e3181e40dde
|
[11]
|
Zhu, H., Xu, X., Wang, H., et al. (2022) Secondary Preven-tion of Antithrombotic Therapy in Patients with Stable Cardiovascular Disease at High Ischemic Risk: A Network Me-ta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 9, Article 1040473. https://doi.org/10.3389/fcvm.2022.1040473
|
[12]
|
Jones, W.S., Baumgartner, I., Hiatt, W.R., et al. (2017) Ticagrelor Compared with Clopidogrel in Patients with Prior Lower Extremity Revascularization for Peripheral Artery Disease. Circulation, 135, 241-250.
https://doi.org/10.1161/CIRCULATIONAHA.116.025880
|
[13]
|
Samoš, M., Fedor, M., Kovář, F., et al. (2016) Ticagrelor: A Safe and Effective Approach for Overcoming Clopidogrel Resistance in Patients with Stent Thrombosis? Blood Coagulation & Fibrinolysis, 27, 117-120.
https://doi.org/10.1097/MBC.0000000000000406
|
[14]
|
Bonaca, M.P., Bhatt, D.L., Storey, R.F., et al. (2016) Ti-cagrelor for Prevention of Ischemic Events after Myocardial Infarction in Patients with Peripheral Artery Disease. Jour-nal of the American College of Cardiology, 67, 2719-2728.
https://doi.org/10.1016/j.jacc.2016.03.524
|
[15]
|
Abtan, J., Bhatt, D.L., Elbez, Y., et al. (2023) External Applicability of the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) Trial: An Analysis of Patients with Diabetes and Coronary Artery Disease in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. International Journal of Cardiology, 370, 51-57. https://doi.org/10.1016/j.ijcard.2022.10.132
|
[16]
|
Miyashita, Y., Saito, S., Miyamoto, A., Iida, O. and Nanto, S. (2011) Cilostazol Increases Skin Perfusion Pressure in Severely Ischemic Limbs. Angiology, 62, 15-17. https://doi.org/10.1177/0003319710371619
|
[17]
|
O’Donnell, M.E., Badger, S.A., Sharif, M.A., et al. (2009) The Effects of Cilostazol on Exercise-Induced Ischaemia-Reperfusion Injury in Patients with Peripheral Arterial Disease. Eu-ropean Journal of Vascular and Endovascular Surgery, 37, 326-335. https://doi.org/10.1016/j.ejvs.2008.11.028
|
[18]
|
Brown, T., Forster, R.B., Cleanthis, M., et al. (2021) Cilostazol for Intermittent Claudication. Cochrane Database of Systematic Reviews, No. 6, Article No. CD003748. https://doi.org/10.1002/14651858.CD003748.pub5
|
[19]
|
Bonaca, M.P., Gutierrez, J.A., Creager, M.A., et al. (2016) Acute Limb Ischemia and Outcomes with Vorapaxar in Patients with Peripheral Artery Disease: Results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients with Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation, 133, 997-1005. https://doi.org/10.1161/CIRCULATIONAHA.115.019355
|
[20]
|
Merlini, P.A., Bauer, K.A., Oltrona, L., et al. (1994) Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction. Circulation, 90, 61-68. https://doi.org/10.1161/01.CIR.90.1.61
|
[21]
|
Kindell, D.G., Marulanda, K., Caruso, D.M., et al. (2023) In-cidence of Venous Thromboembolism in Patients with Peripheral Arterial Disease after Endovascular Intervention. Jour-nal of Vascular Surgery: Venous and Lymphatic Disorders, 11, 61-69. https://doi.org/10.1016/j.jvsv.2022.08.009
|
[22]
|
Anand, S., Yusuf, S., Xie, C., et al. (2007) Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. New England Journal of Medicine, 357, 217-227. https://doi.org/10.1056/NEJMoa065959
|
[23]
|
Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group (2000) Efficacy of Oral Anticoagulants Compared with Aspirin after Infrainguinal Bypass Surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): A Randomised Trial. Lancet, 355, 346-351. https://doi.org/10.1016/S0140-6736(99)07199-8
|
[24]
|
Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., et al. (2010) Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 363, 2499-2510.
https://doi.org/10.1056/NEJMoa1007903
|
[25]
|
Anand, S.S., Bosch, J., Eikelboom, J.W., et al. (2018) Rivaroxaban with or without Aspirin in Patients with Stable Peripheral or Carotid Artery Disease: An International, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet, 391, 219-229. https://doi.org/10.1016/S0140-6736(17)32409-1
|
[26]
|
Bonaca, M.P., Bauersachs, R.M., et al. (2020) Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine, 382, 1994-2004. https://doi.org/10.1056/NEJMoa2000052
|
[27]
|
陈隽, 周一薇, 李秀娟. 症状性下肢动脉疾病抗栓治疗分析[J]. 临床荟萃, 2021, 36(10): 937-941.
|